comprehensive -WSS

comprehensive

author：focus 2025-09-27 10:04:34 - browse：3613

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

WSS

Prior authorization will have to move faster under new Biden rule

Dewpoint Therapeutics lays off staff after losing partnerships

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Why palliative psychiatry is worth discussing

STAT readers on older presidents, polypills, Medicare, and more

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Wikipedia

comprehensive

focus

Activists slam private health insurers over coverage restrictions

STAT readers on older presidents, polypills, Medicare, and more

Apple is now the first public company to be valued at $3 trillion

Dario to buy mental health app maker Twill in cash and stock deal

Walensky prepares to leave CDC — and Congress — behind

The tragedy of Johnson & Johnson’s Covid vaccine

Medicare proposal to cover medical devices draws a mixed reaction

Test for long Covid? Researchers find new clue in blood samples

Psychedelics group wrestles with new pharma identity

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

hotspot

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

In utero gene editing: an explainer

A new nitrogen execution bill also undermines medical licensing

Medicare inequities exacerbate Puerto Rico’s health disparities

focus

entertainment

hotspot

hotspot